— Know what they know.
Not Investment Advice

CHRS NASDAQ

Coherus Oncology, Inc.
1W: -3.7% 1M: -12.8% 3M: -3.7% YTD: +14.6% 1Y: +92.4% 3Y: -69.7% 5Y: -89.6%
$1.61
+0.04 (+2.55%)
 
Weekly Expected Move ±11.0%
$1 $1 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 32 · $197.1M mcap · 116M float · 1.10% daily turnover · Short 59% of daily vol

Cash Flow Trends

Operating Cash Flow
-$139M -577.7% ▼
Capital Expenditures
$0 +0.0% ▲
Free Cash Flow
-$139M -577.7% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$37M -262.1% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$287M-$292M-$238M$29M$168M
Depreciation & Amort.$3M$4M$4M$5M$0
Stock-Based Comp.$51M$51M$0$28M$0
Change in Working Capital$42M-$79M-$37M$56M-$6M
Other Non-Cash Items$143M$75M$96M-$138M-$301M
Operating Cash Flow-$37M-$241M-$175M-$20M-$139M
— Investing Activities —
Capital Expenditures-$1M-$2M-$286K$0$0
Acquisitions (Net)$1M$0$845K$0$0
Investment Purchases-$182M-$127M-$20M$0-$104M
Investment Sales$181M$0$158M$15M$21M
Other Investing-$137M-$37M$6M$215M$457M
Investing Cash Flow-$138M-$167M$145M$230M$375M
— Financing Activities —
Net Debt Issuance-$672K$50M$0-$223M-$233M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$54M-$2M-$5M$35M-$49M
Financing Cash Flow$52M$54M$70M-$187M-$274M
Net Change in Cash-$124M-$354M$39M$23M-$37M
Cash End of Period$418M$64M$103M$126M$89M
Free Cash Flow-$39M-$243M-$175M-$20M-$139M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms